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Abstract
Sitagliptin is a dipeptidyl peptidase-4 (DPP IV, CD26) inhibitor indicated for treatment of Type II diabetes as a second 
line therapy after metformin. We report fifteen sitagliptin intolerant patients who developed anterior and posterior 
rhinorrhea, cough, dyspnea, and fatigue. Symptoms typically developed within 1 to 8 weeks of starting, and resolved 
within 1 week of stopping the drug. Peak expiratory flow rates increased 34% in 8 patients who stopped sitagliptin. 
Similar changes were found in 4 out of 5 persons who had confirmatory readministration. Chart review identified 17 
patients who tolerated sitagliptin and had no symptomatic changes. The sitagliptin intolerant group had higher rates 
of clinically diagnosed allergic rhinitis (15/15 vs. 6/18; p = 0.00005), Fisher's Exact test) and angiotensin converting 
enzyme inhibitor - induced cough (6/13 vs. 1/18; p = 0.012). Nasal and inhaled glucocorticoids may control the 
underlying allergic inflammation and abrogate this new sitagliptin - induced pharmacological syndrome. Potential 
mucosal and central nervous system mechanisms include disruption of neuropeptides and/or cytokines that rely on 
DPP IV for activation or inactivation, and T cell dysfunction.
Background
Sitagliptin is a selective dipeptidylpeptidase-4 (DPP IV,
CD26, EC 3.4.14.5) inhibitor indicated for the treatment
of T ype II dia bet es me llit us [1]. Dia betics tr ea t ed with
sitagliptin (Januvia™, Merck & Co., Inc., Whitehouse Sta-
tion, N.J.) develop "upper respiratory tract infections",
"cough", and "sore throat" in 5% to 6% of subjects [2].
Similar rates for these adverse events have been reported
for the other DPP IV inhibitors vidagliptin [3] and saxa-
gliptin [4]. Infections from all causes had a 34% relative
risk increase (95% confidence interval 10% to 64%, P =
0.004) for sitagliptin compared to other diabetes treat-
ments [5]. Previous studies have predicted that airway
adverse events may occur with this class of drugs [6-9].
We propose that inflammatory changes may be occurring
that were coded as infections in clinical studies. This is of
importance in balancing the risk: benefit ratio for treat-
ment with DPP IV inhibitors [10,11].
Two subjects who had recently started taking sitagliptin
presented to our clinics with rhinorrhea, cough, dyspnea
and fatigue, and requested evaluations for drug sensitiv-
ity. We challenged these index cases to determine if sita-
gliptin induced a reproducible syndrome. When the
challenges were affirmative, we reviewed charts to iden-
tify other sitagliptin - treated subjects. We identified sita-
gliptin intolerant and tolerant groups, and began an
analysis of potential mechanism(s) and risk factors for
this new drug - induced syndrome.
Methods
The index cases were type II diabetic subjects who pre-
sented to an urban tertiary allergy center and a rural fam-
ily practice clinic with upper and/or lower airway
symptoms shortly after starting oral sitagliptin (25 and
100 mg per day, respectively). Chart reviews at the rural
clinic identified 205 diabetics including 31 who had
received sitagliptin as an adjunct to combinations of met-
formin, sulfonylurea and insulin. Symptoms of fatigue,
anterior and posterior rhinorrhea, cough, and sensations
of wheezing or dyspnea defined a "sitagliptin intolerant
population". Fifteen intolerant and seventeen tolerant
patients were identified and examined for potential risk
factors and mechanisms of sitagliptin - related com-
plaints. Outpatient evaluations included history, review
of medication - related adverse events, physical examina-
tion, and, when possible, measurement of peak expiratory
flow rates. Spirometry and allergy skin tests were per-
formed at the urban clinic. Peak expiratory flow rate
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(PEFR) and subjective impressions of anterior and poste-
rior nasal discharge, cough, dyspnea, and fatigue symp-
toms scores (0 to 10 ordinal scales with 0 = none and 10 =
worst in life) were assessed by the physician at the visit
when sitagliptin was stopped, and by the patient for a 1 to
2 week follow-up period. Health insurance restrictions
and referral opportunities precluded allergy testing for
most of rural diabetics. Clinical diagnoses of allergic
rhinitis and asthma were inferred from Allergic Rhinitis
In Asthma (ARIA) [12] and Global Initiative for Asthma
(GINA) [13] guidelines. Specific details are given in the
Case Reports.
The diagnosis of allergic rhinitis was made clinically
using the symptom algorithm of the ARIA guidelines
[12]. These rhinitis subjects had rhinitis with itch, sneez-
ing, watery nasal and ocular discharge that was improved
by nasal glucocorticoids, monteluklast, and/or antihista-
mine therapy during their target season(s). This rural
patient population was unique because tree nursery
farms were the chief agricultural industry in this naturally
forested geographical area. The non-indigenous trees
contributed a large additional burden to the high levels of
diverse hardwood forest pollens. Community members
paid careful attention to the timing of eye and nose itch-
ing, sneezing, congestion and cough symptoms in the set-
ting of widespread commercial knowledge of pollination
times for each cultivar. Allergic rhinitis was diagnosed
frequently (19/31, 61%) in this group. A subsequent anal-
ysis of 330 consecutive practice patients found that 59%
met allergic rhinitis criteria using the ARIA algorithm
[12]. This compares to 42.5% in the 2005-2006 U.S.
National Health and Nutrition Examination Survey
where atopy was defined by having at least one positive
result to 15 allergen tests [14]. Five patients (Cases 1, 3, 6,
7, 21) had positive skin tests to further support their diag-
nosis.
Five patients wanted to restart the drug. Two wanted to
know if sitagliptin was responsible for their symptoms,
while three others tried because of its beneficial hypogly-
caemic and weight effects. Each patient was counselled
about the probable return of symptoms according to clin-
ical standards of care. Patients measured PEFR and clini-
cal symptoms after restarting the sitagliptin to assess
drug effects. This amounted to a dechallenge - rechal-
lenge paradigm [15,16]. Placebo, nocebo and other
related effects must be considered in reviewing the
results of these open drug administrations [17-19].
Statistical differences between groups were determined
by two-tailed unpaired Student's t-tests and Fisher's Exact
test.
Results
Thirty three diabetics using sitagliptin were identified.
Fifteen intolerant patients had combinations of fatigue,
anterior and posterior rhinorrhea, cough, sensations of
wheezing, and dyspnea. Four had obesity - related restric-
t i o n  o n  s p i r o m e t ry .  E i g h t e e n  p a t i e n t s  w e r e  t o l e r a n t  t o
sitagliptin and did not develop these symptoms.
Significantly more of the intolerant individuals had
allergic rhinitis (15/15) than the sitagliptin tolerant (6/18)
group (p = 0.00005). Angiotensin converting enzyme
inhibitor (ACEI) intolerance was more common in those
intolerant to sitagliptin (6/13) compared to tolerant
patients (1/18; p = 0.012). Overall, patients with a clinical
history of allergic rhinitis had more ACEI intolerance (7/
19) than patients without that history (0/12) (p = 0.019).
The two groups were equivalent for age, gender, hemo-
globin A1c, the proportions treated with metformin, sul-
fonylureas and insulin, sitagliptin doses, and rates of
improved glucose control and weight loss on sitagliptin (p
> 0.20) (Figure 1). These patients were taking multiple
medications as is typical for diabetic patients. The most
common were ranked as ACE inhibitors, statins, other
antihypertensives and antidepressant medications. Their
use was similar in both groups. Each patient's combina-
tion of medications was evaluated for cytochrome P450
Figure 1 Demographics, treatments and responses for the sita-
gliptin intolerant and tolerant groups. Treatments were metformin 
(Met), sulfonylureas (SU) and insulin. (* Cases 16 and 18 were treated 
with chronic low dose methotrexate for rheumatoid arthritis. † Case 7 
died of a pulmonary embolism, and Case 24 had a sudden unexplained 
death. n.d., not determined.)




Sitaglipin Intolerant Group 
1  F  55  31.1  Yes  Yes  No  5.9  Yes  No 
2  F  56  23.1  Yes  Yes  No  8.3/7.2  Yes  Yes 
3  F  55  48.1  Yes  Yes  No  8.9  No  20 kg 
4  M  66  29.1  Yes  Yes  No  7.8/9.2  Yes  No 
5  F  71  38.0  Yes  Yes  No  7.8  Yes  No 
6  F  64  42.1  No  No  Yes  9.9  Yes  No 
7
†  F  60  39.3  Yes  Yes  No  6.2  Yes  No 
8  F  38  33.0  Yes  Yes  No  9.1  Yes  Yes 
9  M  69  47.7  No  Yes  No  7.3  Yes  No 
10  F  75  29.2  No  Yes  No  8.4  Yes  No 
11  M  32  37.7  Yes  Yes  No  8.8  Yes  No 
12  F  63  32.5  Yes  Yes  No  8.2  Yes  Yes 
13  M  62  19.0  Yes  No  No  8.1  Yes  Yes 
14  F  59  43.0  Yes  No  No  10.6  Yes  No 
15  F  39  39.0  Yes  Yes  No  10.2  Yes  Yes 
Sitagliptin Tolerant Group 
16*  F  69  30.3  No  Yes  No  6.4  Yes  Yes 
17  F  61  35.7  No  Yes  No  7.3  Yes  No 
18*  F  59  41.1  No  No  Yes  10  Yes  n.d. 
19  F  52  29.6  Yes  No  No  8.9  Yes  n.d. 
20  M  44  34.0  Yes  No  No  7.1  Yes  Yes 
21  F  72  23.8  Yes  Yes  No  7.6  Yes  No 
22  M  58  28.8  Yes  Yes  No  9.2  Yes  No 
23  M  77  28.8  Yes  Yes  No  8.4  Yes  No 
24
†  M  64  41.6  No  No  Yes  8.2  Yes  No 
25  F  48  42.7  Yes  Yes  No  7.6  No  Yes 
26  M  64  25.9  Yes  Yes  No  7.7  Yes  No 
27  F  53  35.3  No  No  Yes  8.6  Yes  No 
28  M  38  33.0  Yes  No  No  7.5  Yes  Yes 
29  M  52  38.5  Yes  Yes  Yes  12.0  Yes  No 
30  F  30  40.6  Yes  Yes  No  8.7  Yes  No 
31  M  38  35.7  No  No  No  6.7  Yes  No 
32  M  55  39.4  Yes  No  No  9.0  Yes  Yes 
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and other drug interactions that could have caused simi-
lar patterns of symptoms. However, none were found.
All sitagliptin intolerant subjects had seasonal or
perennial allergic rhinitis treated with intermittent anti-
histamines and nasal steroid sprays (Figure 2). Those with
mild intermittent asthma generally had been prescribed
montelukast, an inhaled glucocorticoid or inhaled
albuterol which were used on an ad hoc basis. The
median time for onset of sitagliptin - related symptoms
was 3 weeks (range 1 to 8 weeks) except for Cases 10 and
15. Case 10 began taking sitagliptin during ragweed sea-
son while taking montelukast and had no adverse symp-
toms. However, during the next ragweed season she
developed intolerable rhinitis symptoms despite the
montelukast. Symptoms resolved within a week of stop-
ping sitagliptin even though the ragweed season contin-
ued unabated. Case 15 began having symptoms during
the local grass season. Symptoms persisted for months
into the winter and resolved within a week of stopping
sitagliptin.
Anterior and/or posterior rhinorrhea, fatigue, cough
and the sensation of wheezing or dyspnea developed in all
eleven intolerant patients, with the following exceptions.
Fatigue may have been related to concomitant ischemic
heart disease in Cases 6, 12 and 13. Obesity - related air-
flow restriction was present in Cases 3, 9, 10 and 12. Case
5 had no wheeze or dyspnea, while Case 8 had no cough,
wheezing or dyspnea. Case 11 did not have symptoms
Figure 2 Sitagliptin adverse events. The presence of allergic rhinitis (AR) and its treatment (AR Rx), ACE inhibitor intolerance (ACE intol.), duration 
of sitagliptin treatment before symptoms began, the nature of the symptoms, and effects of discontinuation and subsequent challenge are shown. 
PEFR values are shown as % change after stopping sitagliptin, or normalized % of predicted (% pred) for tolerant subjects. Five subjects had restrictive 
patterns on spirometry that may have been related to obesity. Their PEFRs were not reported. Effective use of intranasal and inhaled corticosteroids 
(INS+ICS) prevented the return of symptoms for Case 5. Cases 16 and 18 used chronic methotrexate for rheumatoid arthritis (*). Case 23 developed a 
rash with sitagliptin which recurred on rechallenge. Case 9 now requires hemodialysis for hypertensive renal failure. Case 25 developed non Hodgkins 
lymphoma. Case 7 died from a pulmonary embolism. Case 24 had a sudden unexpected death. (nil, no complaints; n.d., not determined).
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PEFR  Symptoms 
% 
PEFR 
Sitagliptin Intolerant Group 
1  Yes  Yes  Yes  n.d.  Yes  Yes  Yes  Yes  1 week  38%  Positive  30% 
2  Yes  Yes  Yes  n.d.  Yes  Yes  Yes  Yes  1 week  49%  Positive  19% 
3  Yes  Yes  Yes  7 weeks  Yes  Yes  Yes  Yes  n.d.  Restriction  Positive  n.d. 
4  Yes  nil  nil  8 weeks  Yes  Yes  Yes  Yes  1 week  n.d.  Positive  11% 
5  Yes  Yes  nil  1 week  Yes  Yes  Yes  Yes  1 week  33%  INS+ICS  0% 
6  Yes  Yes  Yes  2 weeks  Yes  Yes  Yes  Yes  1 week  31%  n.d.  n.d. 
7  Yes  nil  nil  n.d.  Yes  Yes  Yes  Yes  1 week  17%  n.d.  n.d. 
8  Yes  Yes  No Rx  2 weeks  nil  Yes  nil  Yes  1 week  n.d.  n.d.  n.d. 
9  Yes  Yes  nil  4 weeks  Yes  Yes  Yes  Yes   1 week  Restriction  n.d.  n.d. 
10  Yes  Yes  nil  54 weeks  Yes  Yes  nil  Yes  1 week  Restriction  n.d.  n.d 
11  Yes  Yes  nil  2 weeks  nil  Yes  nil  nil  1 week  80% pred  Positive  n.d. 
12  Yes  Yes  Yes  1 week  Yes   Yes  Yes  Yes  1 week  Restriction  n.d.  n.d. 
13  Yes  Yes  No Rx  n.d.  Yes  Yes  Yes  heart  1 week  0%  n.d.  n.d. 
14  Yes  Yes  nil  n.d.  Yes  Yes  nil  Yes  1 week  73%  n.d.  n.d. 
15  Yes  Yes  Yes  24 weeks  Yes  Yes  Yes  nil  1 week  80% pred  n.d.  n.d. 
Sitagliptin Tolerant Group 
16*  Yes  Yes  nil  12 weeks  Spring  Spring  Spring  Spring  2 weeks  74% pred  n.d.  n.d. 
17  Yes  Yes  nil  8 weeks  nil  Viral  nil  nil  8 weeks  n.d.  n.d.  n.d. 
18*  Yes  Yes  Yes  nil  nil  nil  nil  nil  nil  n.d.  n.d.  n.d. 
19  Yes  Yes  nil  nil  nil  nil  nil  nil  nil  n.d.  n.d.  n.d. 
20  Yes  nil  nil  nil  nil  nil  nil  nil  nil  n.d.  n.d.  n.d. 
21  Yes  nil  nil  nil  nil  nil  nil  nil  nil  n.d.  n.d.  n.d. 
22  nil  nil  nil  nil  nil  nil  nil  nil  nil  95% pred  n.d.  n.d. 
23  nil  nil  nil  nil  nil  nil  nil  nil  nil  107% pred  n.d.  n.d. 
24  nil  nil  nil  nil  nil  nil  nil  nil  nil  n.d.  n.d.  n.d. 
25  nil  nil  nil  nil  nil  nil  nil  nil  nil  n.d.  n.d.  n.d. 
26  nil  nil  nil  nil  nil  nil  nil  nil  nil  n.d.  n.d.  n.d. 
27  nil  nil  nil  nil  nil  nil  nil  nil  nil  n.d.  n.d.  n.d. 
28  nil  nil  nil  nil  nil  nil  nil  nil  nil  n.d.  n.d.  n.d. 
29  nil  nil  nil  nil  nil  nil  nil  nil  nil  n.d.  n.d.  n.d. 
30  nil  nil  nil  nil  nil  nil  nil  nil  nil  n.d.  n.d.  n.d. 
31  nil  nil  nil  nil  nil  nil  nil  nil  nil  n.d.  n.d.  n.d. 
32  nil  nil  nil  nil  nil  nil  nil  nil  nil  Restriction  n.d.  n.d. 
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during a first, short trial with sitagliptin, but developed
rhinitis when the drug was restarted during his usual,
symptomatic, tree pollen season. His symptoms disap-
peared within 1 week of stopping sitagliptin.
PEFR increased between 0% and 73% after sitagliptin
was stopped. Overall, PEFR increased 34% (23% to 44%)
(mean, 95% confidence interval) following cessation of
sitagliptin treatment and challenges. However, only Cases
2 and 14 had significant changes in spirometry (e.g.
FEV1/FVC) suggesting that reduced PEFR on sitagliptin
may have been related to potential decreases in effort
without intrapulmonary bronchoconstriction.
Rhinorrhea, cough and fatigue generally improved in
the first week off sitagliptin, while PEFR took 1 to 3 weeks
to improve. Sitagliptin was readministered to five intoler-
ant patients (see Case Reports). Four had an identical set
of symptoms recur showing the reproducibility of their
responses (Figure 2). The fifth person had moderate aller-
gic rhinitis with mild seasonal asthma, but became symp-
tom free after becoming highly compliant with intranasal
and inhaled mometasone furoate. This suggested that
proper identification of atopy and institution of indicated
glucocorticoid therapy prevented the adverse airway
effects of sitagliptin. This rural population seems to have
had underappreciated their mild intermittent asthma,
and so were undertreated.
Seventeen patients were tolerant to sitagliptin and did
not develop syndromic rhinorrhea, cough, fatigue, dysp-
nea or sensation of wheezing with the drug. However,
two did develop some symptoms. Case 16 developed
cough, rhinorrhea, wheeze and fatigue during tree pollen
season with PEFR 74% of predicted. Sitagliptin had no
effect on the pattern of symptoms. Rhinitis and asthma
symptoms resolved within 2 weeks of initiating nasal and
inhaled fluticasone propionate. Nasal fluticasone and the
use of methotrexate for rheumatoid arthritis prevented
recurrence of symptoms during grass and ragweed sea-
sons. Case 16 had viral rhinitis lasting 8 weeks. Montelu-
kast controlled the seasonal rhinitis. Cases 18 and 19 took
nasal steroids and did not develop symptoms. Case 18
had long standing rheumatoid arthritis treated with
methotrexate. Case 20 developed seasonal rhinitis symp-
toms which improved with nasal steroids the year after
stopping sitagliptin. Case 21 had completed immuno-
therapy years before sitagliptin administration and did
not develop symptoms. The remaining eleven subjects
had none of these symptoms. Two had normal spirome-
try and one had obesity - related restriction.
Case Reports
Case 1
A 55 yr old, atopic, white female developed Type II diabe-
tes. She had hypothyroidism, ragweed-induced seasonal
asthma, hypertension and history of ACEI cough. She
started sitagliptin 100 mg by mouth daily in the early win-
ter and then developed nasal congestion, post-nasal drip,
and a throat-clearing cough. A frontal headache devel-
oped that gradually worsened over time. She decided to
stop the drug when her peak expiratory flow rate (PEFR)
dropped to 450 L/min (Figure 3). The next day her head-
ache and congestion were gone. The cough ceased 3 days
later. PEFR rose to 620 L/min. She also noticed more
vigor and realized she had become very fatigued on sita-
gliptin. She requested a supervised course of sitagliptin
(50 mg) to determine if these symptoms represented a
reproducible, drug - induced syndrome. Symptoms
recurred over the next 3 days. Her lowest PEFR was 430
L/min after 2 weeks. She scored congestion severity, post-
nasal drip, throat clearing and tiredness/decreased
energy at 5 to 8 out of 10 and headache as 5 to 7 out of 10.
Cough was intermittent during these 2 weeks. After stop-
ping the drug, all symptoms disappeared and PEFR
returned to her normal.
Case 2
A 55 year old, white female had Type II diabetes, hypo-
thyroidism, hypertension with history of ACEI cough,
persistent mild allergic rhinitis with seasonal worsening
to moderate levels, and chronic moderate persistent
asthma. After starting sitagliptin 100 mg by mouth daily,
she developed severe rhinorrhea and cough which per-
sisted for months.
When she returned for follow-up, her PEFR was 176 L/
min. Her FEV1/FVC was 63% and FEF25%-75% was 43%
of predicted. Sitagliptin was stopped. She scored her
postnasal drip as 3/10 two days after stopping the drug.
The cough resolved over several days and her PEFR rose
to 280 L/min after 12 days.
Later, she asked to restart sitagliptin because of the
beneficial hypoglycaemic benefits. Unfortunately, this
was during her typical tree pollen-induced rhinitis
period. PEFR dropped to 180 L/min and rhinorrhea
Figure 3 Case 1. Increased dyspnea was noted while on sitagliptin 
(week 0). Peak flows increased rapidly within several days of stopping 
the drug. Restarting sitagliptin after 2 1/2 weeks led to a progressive, 
30% decline in PEFR. PEFR again returned to her usual after stopping 



















)  Stop sitagliptin 
Restart 
drug 
30% drop Baraniuk and Jamieson Allergy, Asthma & Clinical Immunology 2010, 6:8
http://www.aacijournal.com/content/6/1/8
Page 5 of 9
scores increased to 9/10 despite the concomitant, but
intermittent, use of inhaled steroids and bronchodilators.
Cough did not recur, but she stopped the sitagliptin
because of dyspnea. Dyspnea resolved within one day,
and rhinorrhea in 2 days (0/10). Two weeks later, her
FEV1/FVC had increased to 79.1%, FEF25%-75% to 69%
of predicted, and PEFR to 320 L/min. The next year while
off sitagliptin, her maximum rhinorrhea score during the
tree pollen season was 5/10.
Fatigue at the end of her first sitagliptin treatment
period was 7/10. This dropped to 4/10 after stopping the
drug. During the challenge period, her fatigue again
reached 7/10. Fatigue decreased to 3/10 within 3 days of
stopping the sitagliptin challenge, and remained low
throughout her tree pollen rhinitis season.
Case 3
A morbidly obese 55 yr old African-American woman
had metabolic syndrome, atopic and aspirin-induced
asthma and rhinitis, and history of ACEI cough. Atopy
and asthma were controlled by inhaling one puff of 500
μg fluticasone propionate/50 μg salmeterol twice per day,
fexofenadine (180 mg), nasal mometasone, occassional
nebulized budesonide (0.25 mg) plus levalbuterol treat-
ments, and omalizumab (375 mg sc every 2 weeks). Sita-
gliptin (50 mg per day) was added to metformin and
glucophage. She noted progressive fatigue and loss of
energy, but no cough or alteration in her intermittent pat-
tern of wheezing. Although she lost 20 kg, sitagliptin did
not improve glucose control, and so it was discontinued.
Several months later the drug was restarted to maintain
the weight reduction. Eight weeks later she reported
increased fatigue (4/10 became 8/10), cough (0/10 rose to
?6/10), and dyspnea (5/10 increased to 8-9/10). PEFR was
persistently low at 250 L/min. She promptly developed a
parainfluenza infection complicated by acute rhinosinus-
itis that required azithromycin, and a prolonged asthma
exacerbation that required 6 weeks of prednisone and
nebulized budesonide (0.5 mg) and levalbuterol (four
times per day). This was her worst exacerbation in over
three years, and was temporally related to restarting the
sitagliptin.
Case 4
This 66 yr old male developed fatigue, rhinorrhea, cough
and sensation of wheezing after 8 weeks of sitagliptin.
These symptoms cleared after discontinuing the drug.
Sitagliptin was restarted to determine the relationship to
his symptoms. Symptom scores increased to 3/10, but
PEFR was not recorded. Again the sitagliptin was
stopped. Symptom scores dropped to 1/10 and PEFR
improved by 11% after 1 week off sitagliptin. His chal-
lenge was for proof of principle and sitagliptin was dis-
continued before severe symptoms developed.
Case 5
Sitagliptin caused rhinorrhea, cough, dyspnea and fatigue
in this 71 yr old female. Symptoms cleared after stopping
the drug. She had moderately severe allergic rhinitis with
intermittent asthma, but used nasal fluticasone propi-
onate occasionally for relief of the most severe symptoms.
However, during sitagliptin challenge, she adhered
strictly to daily inhaled and intranasal mometasone
furoate. Her symptoms did not recur despite entering her
generally severe fall ragweed season. This may suggest
that appropriate, prophylactic glucocorticoid treatment
of allergic inflammation may prevent the sitagliptin -
induced symptom complex.
Internet Case
An additional subject was identified by an internet search
[20]. Cough was the predominant symptom. The subject
had a history of ACE inhibitor cough, but had abstained
from ACE inhibitors for several months during sitagliptin
therapy.
Discussion
Factors accounting for sitagliptin pathophysiology can be
inferred from a review of DPP IV function and prece-
dents set by other peptidases. This is highly relevant for
allergists who may see patients with similar symptoms or
apparent drug reactions. The most recent NICE clinical
guidelines recommend addition of a DDP IV inhibitor as
second line treatment with metformin instead of a sul-
phonylurea to avoid hypoglycemia [21]. Therefore, physi-
cians may prescribe sitagliptin more often for diabetes
control. The mechanisms of DPP IV in vivo may also be
relevant to recent reports of 88 cases of pancreatitis by
the FDA [22]. We did not encounter any pancreatitis in
our study cohort.
DPP IV is a 110 kDa cell surface glycoprotein with ser-
ine exopeptidase activity that cleaves proline dipeptides
from the N-terminus of polypeptides. In diabetes it
cleaves the N-terminal tyrosine-proline dipeptide from
the glucagon-like peptide-1 (GLP-1), glucose-dependent
insulinotropic polypeptide (GIP), gastric inhibitory pep-
tide, and pituitary adenylate cyclase activating peptide
(PACAP). These incretins are released postprandially
from the gut and stimulate insulin secretion [1]. DPP IV
promotes hyperglycemia by rapidly inactivating these
peptides. However, inhibition of DPP IV maintains the
incretins at physiological levels that can increase insulin
secretion.
DPP IV is the prototype of the DPP IV activity and/or
structure homologue (DASH) protein family [23]. The
family includes DPP7, DPP8, DPP9, DPP-IV-β, fibroblast
activation protein (FAP), and attractin. The common fea-
ture is their specificity for cleaving proline from the N-
terminal of proteins and peptides. Many of the activitiesBaraniuk and Jamieson Allergy, Asthma & Clinical Immunology 2010, 6:8
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of DPP IV discussed below were identified using rela-
tively nonselective enzyme antagonists. More specific
DPP IV and DPP 8/9 antagonists now suggest that some
"DPP IV" actions may be mediated by DPP8, DPP9 or
other members of this family.
These effects of DPP IV inhibition on airway and other
organ symptoms were predictable given the relationships
between ACEI and cough, neutral endopeptidase (NEP,
CD10; EC 3.24.11) with neurogenic inflammation, and
complement C1 esterase inhibitor and hereditary angion-
eurotic edema [24,25].
Angiotensin converting enzyme inhibitors (ACEI) are
the precedent for respiratory adverse events related to
peptidolytic drugs [16]. The mechanism of ACE inhibi-
tor-induced cough remains unresolved, but likely
involves the protussive mediators bradykinin and sub-
stance P, agents that are degraded by ACE and therefore
accumulate in the upper respiratory tract or lung when
the enzyme is inhibited [26]. Prostaglandins are stimu-
lated by bradykinin and may contribute to the cough.
These mediators likely stimulate Type C vagal afferent
neurons to provoke the brainstem cough reflex. The pro-
totypical ACEI, captopril, did not enhance the direct
vasodilatory or secretory effects of topically applied vaso-
active intestinal polypeptide (VIP), substance P (SP) or
calcitonin gene-related peptide (CGRP) in the nasal
mucosa of 12 healthy volunteers[27]. This is probably
because ACE has a predominant plasma origin in nasal
mucosa [28]. ACEI also enhance the function of vasodila-
tory bradykinin B1 and B2 receptors [29]. ACEI treat-
ment of rats with genetic deficiency of DPP IV leads to
tachykinin - mediated (substance P, neurokinin A) peri-
tracheal edema [30]. Bradykinin is less likely to be
involved since it is not a DPP IV substrate in rat inflam-
mation [31].
DPP IV can cleave substrates such as eotaxin, regulated
on activation normal T cell expressed and secreted
(RANTES, CCL5), neuropeptide Y (NPY), substance P,
chromogranin B - derived peptides, and other airway
peptides [32,33]. Sitagliptin's inhibition of DPP IV activity
may disrupt the normal functions of these polypeptides,
particularly in inflamed mucosa [6].
NEP degrades, and so regulates, the duration of action
of many small neuropeptides [34]. Like DPP IV, NEP has
reduced expression in chronic rhinosinusitis [7]. This
may reduce mucosal destruction of calcitonin gene
related peptide (CGRP) leading to increased nasal venous
sinusoid engorgement and mucosal thickening, and
enhance neurogenic axon responses ("neurogenic inflam-
mation"). Substance P - induced vasodilation was aug-
mented by DPP IV inhibition in an in vivo porcine nasal
model [6,8]. This potentially neurogenic effect may be
tested in human nasal mucosa using hypertonic saline
nasal provocations [35]. Intranasal steroid treatment
increases NEP, and potentially DPP IV, expression. These
enzymes may be biomarkers of recent mucosal injury and
subsequent recovery.
Neuropeptide Y (NPY1-36) is released with norepi-
nephrine from sympathetic neurons. NPY1-36 is an ago-
nist of Y1 receptors on arterioles and arteriovenous
anastamoses that cause slow onset, prolonged vasocon-
striction and resulting in improved nasal patency [36].
DPP IV removes the N-terminal Tyr-Pro dipeptide from
NPY1-36 to generate NPY3-36 [37]. NPY3-36 binds to Y2
receptors that have relative antagonist properties to Y1
receptor activation. Y2 inhibitory autoreceptors on sym-
pathetic nerves halt the release of norepinephrine and co-
localized NPY. These autoreceptors are also present on
parasympathetic nerves and reduce the release of acetyl-
choline. Any decrease in the peptidolytic generation of
NPY3-36 would decrease the activity of Y2 inhibitory
autoreceptors and so augment sympathetic and parasym-
pathetic neurotransmitter release. The clinical conse-
quences are difficult to predict.
Elevated parasympathetic acetylcholine release is prob-
ably of clinical relevance given the prevalence of rhinor-
rhea in our subjects. Cholinergic stimulation of M3
muscarinic receptors on submucosal glands leads to copi-
ous glandular secretion [38]. This may generate the rhin-
orrhea reported by our subjects and the 5.2% of
sitagliptin users with nasopharyngitis (placebo = 3.3%)
and "upper respiratory tract infection" with the combina-
tion of sitagliptin and pioglitazone (6.3% vs. 3.4% in pla-
cebo) [2]. Cholinergic hypersecretion may be identified
by relief of rhinorrhea when sitagliptin sensitive subjects
use an anticholinergic nasal spray. Analysis of the nasal
secretions may distinguish glandular from vascular
sources of the discharge, and the nature of the offending
peptide(s). These putative peptide DPP IV substrates may
be targets for development of novel rhinorrhea, antitus-
sive, and bronchodilator drugs. Sitagliptin joins the list of
drugs associated with nonallergic mechanisms of rhinitis
[39].
DPP IV immunoreactive material has been localized to
human nasal [6,8] and bronchial [9] mucosa. Immunore-
active material was present in apical (probably serous)
cells of submucosal glands, leukocytes, and endothelial
cells. Biopsies of human nasal tissue from chronic rhinos-
inusitis and bronchi in chronic obstructive diseases dem-
onstrated a positive correlation between DPP IV enzyme
activity and immunoreactivity. DPP IV enzyme activities
in human airway biopsies were inversely related to
mucosal inflammatory cell density [6,8,9]. The leukocytes
were predominantly memory T cells and monocytes [40-
42]. The inverse relationship suggested that products of
the inflammatory process inhibited DPP IV expression.
DPP IV is also known as CD26, and is highly expressed
on memory T cells [43]. CD26 plays an important role inBaraniuk and Jamieson Allergy, Asthma & Clinical Immunology 2010, 6:8
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the proliferation of memory T cells in response to antigen
presentation. Activation of CD26 may increase CD86
expression on CD14 positive monocytes and other anti-
gen presenting cells [44].
DPP IV degrades interferon (IFN) gamma - induced
chemokines, CCL3, CCL5 (RANTES), CCL11, CCL22,
and CXCL12 (stromal cell-derived factor-1 alpha; SDF-
1α). This effect may bias mucosal immune responses
towards TH2 compared to TH1 lymphocyte phenotype.
DPP IV cleavage of the N-terminal dipeptide from CCL5
enhanced chemotaxis of T cells, but not monocytes, in
vitro [41].
A  s o l u b l e  f o r m  o f  D P P  I V  ( s C D 2 6 )  i s  e l e v a t e d  i n
asthma. Plasma sCD26 was positively correlated with
aberrant expression of cell surface CD26 on a wide range
of lymphocytes, altered peripheral eosinophils, Th2-
related chemokines CCL5 and CCL22, and the costimula-
tory molecule soluble cytotoxic T lymphocyte antigen 4
(sCTLA-4) (all P < 0.05) [44]. These cellular mechanisms
may augment the consequences of DPP IV inhibitors dur-
ing tissue inflammation.
Increased attachment of sialic acid residues to the N-
linked polysaccharides of DPP IV makes the enzyme
more acidic. This may reduce enzyme activity and
obstruct access to immunoreactive epitopes and so
reduce immunohistochemical staining and immunoassay
concentrations. Hypersialylated DPP IV has been recog-
nized in rheumatoid arthritis and systemic lupus erythe-
matosus [45]. Lower activities of plasma sCD26/DPP IV
in lupus were correlated with increased disease activity
[42]. The addition of sitagliptin under these circum-
stances of reduced DPP IV activity would further inhibit
DPP IV's peptidolytic function.
The novel observation of reproducible, sitagliptin -
induced fatigue implicates DPP IV substrates in this neu-
ral symptom complex. Fatigue has been associated with
ACEI, angiotensin receptor antagonists, direct renin
inhibitors, beta blockers, calcium channel blockers, and
diuretics [46,47]. However, the relative contributions of
underlying hypertension, congestive heart failure, renal
disease or diabetes versus altered polypeptide cleavage to
fatigue remain to be defined. The reversible fatigue
reported by our patients was directly related to stopping
and restarting sitagliptin. Identification of the as yet
unknown, responsible neurotransmitter(s) or neurotro-
pin(s) offers the potential to understand the molecular
pathogenesis of this complex emotional state, and to
develop drugs that target these putative mechanisms.
Understanding conscious control of cough may also pro-
vide insights into the nature of fatigue given their associa-
tion in this sitagliptin -related syndrome [48].
Central actions of DPP IV inhibitors may be related to
weight loss in Type II diabetics. Low plasma sCD26 levels
were found in anorexia and bulimia nervosa, [49]. NPY is
known to play an important role in hypothalamic control
of appetite and satiety. Sitagliptin inhibition of DPP IV
may prolong the duration of action of prolyl - peptide
substrates that mediate fatigue and weight loss.
Most DPP IV inhibitors have been synthesized with a
fluorovinyl (C = CHF) group where the fluorine atom
acts like the carbonyl oxygen of a peptide bond [50,51].
However, sitagliptin has triflurophenyl and trifluorom-
ethyl groups that may interact more strongly with amino
acid sidechains in the DPP IV active site or other inhibi-
tory locations. Modifications of these groups may lead to
more selective DPP IV inhibitors that do not have effects
on DPP8, DPP9 or other related peptidases. The more
recently released DDP IV inhibitor, saxagliptin, does not
have a fluorinated side chain and the "upper respiratory
symptom" rate is similar in the treated and placebo
groups (7.7%, 7.6%) [4].
Airway inflammation increases mucosal leukocyte den-
sity and may decrease glandular DPP IV activity. If so,
some DPP IV substrates may have a prolonged half-life as
glandular secretagogues. We propose that sitagliptin -
induced inhibition of DPP IV activity may supplement
this inflammatory effect and lead to augmented peptide -
mediated glandular secretion and subsequent post - nasal
drip, irritant - induced throat clearing cough, and
decreased PEFR. Such a result would be consistent with
the clinically defined allergic rhinitis subset of diabetics
who also have a tendency for similar ACEI intolerance.
Topical nasal and bronchial glucocorticoids treatments
control allergic airway inflammation and may permit
DPP IV activity to return to normal. If confirmed, anti-
inflammatory treatment may be beneficial for allergic and
ACEI intolerant diabetics so that they may continue to
safely use sitagliptin when it is clinically indicated for dia-
betes control.
The allergic patients were identified clinically using the
ARIA symptom algorithm. The lack of positive skin test-
ing to confirm allergies is a weakness of this case series.
However, diabetic patients presenting to primary care or
endocrine clinicians may not have had this testing due to
lesser severity of their symptoms, or limitations due to
rural location and health insurance coverage of services.
Lack of access to spirometry limited the diagnosis of
asthma. The unblinded sitagliptin challenges were a logi-
cal starting place for determining if the drug was related
to the rhinitis, cough and fatigue syndrome. However,
placebo and perceptional effects during drug withdrawal
may have led to a misattribution of cause and effect.
Blinded studies will be needed to confirm our explana-
tion of DPP IV drug adverse events in airways and for
fatigue.Baraniuk and Jamieson Allergy, Asthma & Clinical Immunology 2010, 6:8
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Conclusions
A subset of clinically defined allergic rhinitis subjects had
worsening of their symptoms plus fatigue when given
sitagliptin. This and other DPP IV inhibitors have been
reported to cause "upper respiratory infections" in about
5 %  o f  T y p e  I I  d i a b e t i c s .  W e  p r o p o s e  t h a t  u n d e r l y i n g
inflammatory changes in DPP IV activity combined with
further drug - mediated DPP IV inhibition leads to
decreased inactivation of neuropeptides and/or cytokines
that are glandular secretagogues. This plus similar mech-
anism(s) in the brain may be responsible for the rhinor-
rhea, cough and fatigue we associated with sitagliptin
treatment.
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